Ocean Biomedical（8AW0）株式概要オーシャン・バイオメディカル社は、がん、線維症、感染症などの治療薬の発見と開発に注力しているバイオ医薬品企業。 詳細8AW0 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析収益が 100 万ドル未満 ( $0 )マイナスの株主資本 過去5年間で収益は年間3.2%減少しました。 意味のある時価総額がありません ( €1M )+3 さらなるリスクすべてのリスクチェックを見る8AW0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW493,086 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG493,086 investors already sharing narrativesYour Fair Value€Current Price€0.012該当なし内在価値ディスカウントEst. Revenue$PastFuture-84m12016201920222025202620282031Revenue US$1.0Earnings US$0.2AdvancedSet Fair ValueView all narrativesOcean Biomedical, Inc. 競合他社EpigenomicsSymbol: DB:ECXMarket cap: €763.0kbioXXmedSymbol: XTRA:T5O0Market cap: €329.8kRespiratoriusSymbol: DB:HF00Market cap: €25.7mBiomark DiagnosticsSymbol: DB:20BMarket cap: €33.6m価格と性能株価の高値、安値、推移の概要Ocean Biomedical過去の株価現在の株価US$0.01252週高値US$1.0452週安値US$0.003ベータ1.551ヶ月の変化0%3ヶ月変化-20.00%1年変化-98.86%3年間の変化n/a5年間の変化n/aIPOからの変化-99.21%最新ニュースお知らせ • Aug 15Ocean Biomedical, Inc. announced delayed 10-Q filingOn 08/14/2025, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 06Ocean Biomedical Provides Update on the Decision of the Nasdaq Listing and Hearing Review CouncilOn July 31, 2025, Ocean Biomedical, Inc. was notified by Nasdaq that The Nasdaq Stock Market LLC Board of Directors has declined to call for review the May 15, 2025 decision of the Nasdaq Listing and Hearing Review Council in the Company’s appeal proceeding. Accordingly, pursuant to Nasdaq Rule 5820(e)(6), the decision of the Listing Council represents Nasdaq’s final action in this matter. Nasdaq will follow the procedures contained in Nasdaq Rule 5830 and the Securities and Exchange Commission (“SEC”) Rule 12d2-2 to remove the Company’s securities from listing.お知らせ • Jul 26Ocean Biomedical Receives the Decision of the Nasdaq Listing and Hearing Review CouncilOn July 17, 2025, Ocean Biomedical, Inc. received the decision of the Nasdaq Listing and Hearing Review Council pursuant to an appeal by the Company. On April 22, 2025, the Nasdaq Hearings Panel (the “Panel”) issued a decision to delist the Company’s securities from The Nasdaq Stock Market, LLC (the “Exchange” or “Nasdaq”) and suspend trading of the Company’s shares, effective at the opening of business on April 24, 2025. The Company appealed the Panel’s decision to the Listing Council. After considering the written record in this matter, the Listing Council affirms the Panel’s decision to delist the Company from the Nasdaq affirming Nasdaq’s delist decision letter dated April 22, 2025.お知らせ • Apr 24+ 1 more updateOcean Biomedical, Inc.(OTCPK:OCEA) dropped from NASDAQ Composite IndexOcean Biomedical, Inc. has been dropped from the NASDAQ Composite Index (^COMP).お知らせ • Apr 02Ocean Biomedical, Inc. announced delayed annual 10-K filingOn 04/01/2025, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 29Ocean Biomedical, Inc. Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in ChinaOcean Biomedical, Inc. announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells. This newly issued patent will strengthen Ocean Biomedical's intellectual property portfolio and provides protection in one of the world's largest pharmaceutical markets. The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 andPD1, key targets implicated in immune evasion by tumor cells. Ocean Biomedical's bispecific antibody technology represents a potential paradigm shift in cancer immunotherapy. By simultaneously targeting CHI3L1--a key regulator of immune suppression--and PD1, a well-established immune checkpoint, this novel approach has the potential to reinvigorate the immune system's ability to combat tumors more effectively than existing treatments alone. By blocking both pathways, these antibodies could enhance immune-mediated tumor cell destruction, leading to more durable responses and better outcomes for patients. Current immunotherapies are often limited by tumor resistance and immune evasion mechanisms. Ocean Biomedical's technology seeks to address these limitations by taking a multi-pronged approach, blocking two key pathways that tumors use to suppress the immune response. This could result in more robust and sustained tumor control, significantly improving survival rates for patients who currently have limited treatment options. The grant of this patent follows Ocean Biomedical's continued success in securing intellectual property protection across key markets, including the United States and Europe. The company remains committed to leveraging its robust patent estate to drive the development and commercialization of novel immunotherapies. Ocean Biomedical plans to continue collaborating with leading researchers, biopharma partners, and regulatory agencies to strive to accelerate the translation of its discoveries into transformative therapies.最新情報をもっと見るRecent updatesお知らせ • Aug 15Ocean Biomedical, Inc. announced delayed 10-Q filingOn 08/14/2025, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 06Ocean Biomedical Provides Update on the Decision of the Nasdaq Listing and Hearing Review CouncilOn July 31, 2025, Ocean Biomedical, Inc. was notified by Nasdaq that The Nasdaq Stock Market LLC Board of Directors has declined to call for review the May 15, 2025 decision of the Nasdaq Listing and Hearing Review Council in the Company’s appeal proceeding. Accordingly, pursuant to Nasdaq Rule 5820(e)(6), the decision of the Listing Council represents Nasdaq’s final action in this matter. Nasdaq will follow the procedures contained in Nasdaq Rule 5830 and the Securities and Exchange Commission (“SEC”) Rule 12d2-2 to remove the Company’s securities from listing.お知らせ • Jul 26Ocean Biomedical Receives the Decision of the Nasdaq Listing and Hearing Review CouncilOn July 17, 2025, Ocean Biomedical, Inc. received the decision of the Nasdaq Listing and Hearing Review Council pursuant to an appeal by the Company. On April 22, 2025, the Nasdaq Hearings Panel (the “Panel”) issued a decision to delist the Company’s securities from The Nasdaq Stock Market, LLC (the “Exchange” or “Nasdaq”) and suspend trading of the Company’s shares, effective at the opening of business on April 24, 2025. The Company appealed the Panel’s decision to the Listing Council. After considering the written record in this matter, the Listing Council affirms the Panel’s decision to delist the Company from the Nasdaq affirming Nasdaq’s delist decision letter dated April 22, 2025.お知らせ • Apr 24+ 1 more updateOcean Biomedical, Inc.(OTCPK:OCEA) dropped from NASDAQ Composite IndexOcean Biomedical, Inc. has been dropped from the NASDAQ Composite Index (^COMP).お知らせ • Apr 02Ocean Biomedical, Inc. announced delayed annual 10-K filingOn 04/01/2025, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 29Ocean Biomedical, Inc. Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in ChinaOcean Biomedical, Inc. announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells. This newly issued patent will strengthen Ocean Biomedical's intellectual property portfolio and provides protection in one of the world's largest pharmaceutical markets. The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 andPD1, key targets implicated in immune evasion by tumor cells. Ocean Biomedical's bispecific antibody technology represents a potential paradigm shift in cancer immunotherapy. By simultaneously targeting CHI3L1--a key regulator of immune suppression--and PD1, a well-established immune checkpoint, this novel approach has the potential to reinvigorate the immune system's ability to combat tumors more effectively than existing treatments alone. By blocking both pathways, these antibodies could enhance immune-mediated tumor cell destruction, leading to more durable responses and better outcomes for patients. Current immunotherapies are often limited by tumor resistance and immune evasion mechanisms. Ocean Biomedical's technology seeks to address these limitations by taking a multi-pronged approach, blocking two key pathways that tumors use to suppress the immune response. This could result in more robust and sustained tumor control, significantly improving survival rates for patients who currently have limited treatment options. The grant of this patent follows Ocean Biomedical's continued success in securing intellectual property protection across key markets, including the United States and Europe. The company remains committed to leveraging its robust patent estate to drive the development and commercialization of novel immunotherapies. Ocean Biomedical plans to continue collaborating with leading researchers, biopharma partners, and regulatory agencies to strive to accelerate the translation of its discoveries into transformative therapies.お知らせ • Feb 17Ocean Biomedical, Inc., Annual General Meeting, Mar 28, 2025Ocean Biomedical, Inc., Annual General Meeting, Mar 28, 2025. Location: 2511 redwood road, suite 16, utah 84087., woods cross, United Statesお知らせ • Feb 11Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage DevelopmentOcean Biomedical announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC). Specifically, they demonstrate that Ocean’s immunotherapy candidates provide synergy with the TKI therapies (gefitinib and osimertinib) to suppress tumor growth and progression. In addition, the paper’s findings demonstrate that its proprietary cancer immunotherapy candidates have a remarkable ability to restore treatment sensitivity following development of osimertinib resistance. This breakthrough offers a potential paradigm shift in the treatment of Epidermal Growth Factor Receptor (EGFR)-mutant NSCLC and could expand treatment options for patients whose tumors are no longer responding to tyrosine kinase inhibitors. These findings, led by Ocean Biomedical’s Scientific Co-founder Dr. Jack A. Elias in collaboration with researchers at Yale University and Brown University, were published in Translational Oncology and mark the first description of the role of chitinase 3-like-1 (CHi3L1) in EGFR-mutant cancers. The research underscores the ability of Ocean Biomedical’s novel antibody to suppress CHi3L1 activity, leading to significant tumor reduction and, crucially, the reversal of drug resistance in preclinical models. As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating preclinical studies to advance its immunotherapy program and will engage with the FDA this year to align on a regulatory pathway for first-in-human trials. Ocean Biomedical’s advancements come at a time when the oncology field is shifting its focus towards bispecific antibodies, an innovative therapeutic class designed to target multiple cancer mechanisms simultaneously. Bispecific antibodies that target PD-1/PD-L1 and VEGF have shown remarkable efficacy in recent clinical studies, with leading biotech and pharmaceutical companies rapidly investing in this space. Merck’s recent $588 million acquisition of LaNova’s LM-299, a PD-1/VEGF bispecific antibody currently in early-stage clinical trials, underscores the high-value potential of this technology. Industry experts suggest that this wave of investments mirrors the early days of checkpoint inhibitors, highlighting the significant opportunity for Ocean Biomedical to position itself at the forefront of the next major oncology breakthrough. Ocean has also developed bispecific antibodies that combine its anti-CHI3L1 antibody and anti-PD-1 or anti-CTLA4. Studies with these bispecific antibodies have highlighted their impressive efficacy in suppressing tumor growth and progression in preclinical models of NSCLC, malignant melanoma and glioblastoma. The company’s lead oncology program is poised for multiple therapeutic applications: As a standalone therapy for EGFR-mutant NSCLC, In combination with existing TKIs to extend therapeutic response duration, As a salvage therapy to restore treatment efficacy in resistant tumors. With plans to initiate preclinical studies this year, Ocean Biomedical is actively preparing for discussions with the FDA to determine the regulatory pathway for clinical development. This milestone marks a significant step toward bringing its innovative cancer therapy to patients in need.お知らせ • Jan 30Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development PathwayOcean Biomedical announced that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes of Health (NIH) to advance their malaria vaccine research. In parallel, recent U.S. Food and Drug Administration (FDA) Guidance on lipid-encapsulated vaccines may offer an expedited development pathway for their innovative approach. Malaria remains a devastating global health challenge, claiming the lives of over 500,000 children annually in sub-Saharan Africa. Despite hundreds of vaccine development efforts, few have succeeded, largely due to ineffective target selection strategies. Through longitudinal studies of children frequently exposed to infected mosquitoes, the researchers identified a unique protein--glutamic acid-rich protein (GARP)--on the surface of malaria-infected red blood cells. Notably, children who naturally resist severe malaria were found to have developed antibodies against GARP. This discovery, supported by multiple NIH and non-governmental grants, has paved the way for vaccine development. With the support of a $4.6 million non-governmental Foundation grant, Dr. Kurtis' team is now testing three vaccine candidates in non-human primates. The research also explores the feasibility of using lipid-encapsulated messenger ronucleic acid (mRNA) technology as a delivery mechanism. Building on clinical data from millions of individuals who received lipid-encapsulated mRNA vaccines, the FDA has issued new guidance that could facilitate a faster transition to first-in-human trials. Ocean Biomedical intends to leverage this opportunity, with a potential to initiate human trials as early as fourth quarter 2025.お知らせ • Jan 15Ocean Biomedical, Inc. Receives Non-Compliance Notice from Nasdaq Regarding Listing Rules 5620(a) and 5810(c)(2)(G)On January 7, 2025, Ocean Biomedical, Inc. received a notice from Nasdaq that since the Company had not yet held an annual meeting of shareholders within twelve months of the Company's fiscal year ended December 31, 2023, it no longer complies with the Listing Rules (the Rules") for continued listing.(Listing Rules 5620(a) and 5810(c)(2)(G)). Accordingly, this matter serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. This is formal notification that the Nasdaq Hearings Panel (the Panel") will consider this matter in their decision regarding the Company's continued listing on The Nasdaq Capital Market. In that regard, the Company should present its views with respect to this additional deficiency to the Panel in writing no later than January 14, 2025. The Company plans on holding its annual meeting no later than March 31, 2025.お知らせ • Dec 12Ocean Biomedical Receives Non-Compliance Letter Regarding Nasdaq MVLSOn December 5, 2024, Nasdaq sent a letter to Ocean Biomedical, Inc. notifying it that based upon the Company's MVLS for the last 30 consecutive business days, the Company no longer meets this requirement. Consequently, a deficiency exists with regard to the Rule. However, the Rules also provide the Company a compliance period of 180 calendar days in which to regain compliance. If at anytime during this compliance period the Company's MVLS closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting and it may be eligible for additional time to regain compliance, or may face delisting.お知らせ • Dec 10Ocean Biomedical Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid PriceOn December 3, 2024, Ocean Biomedical, Inc. (the Company") received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq's Listing Rules (the Rules") which require listed securities to maintain a minimum bid price of $1 per share. Based upon the closing bid price for the last 30 consecutive business days (October 21, 2024 to December 2, 2024), the Company no longer meets this requirement. However, the Rules also provide the Company a compliance period of 180 calendar days (until June 2, 2025) in which to regain compliance. Pursuant to Rule 5810(c)(3)(C) if at any time during this 180 day period the closing bid price of the Company's security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by June 2, 2025, the Company may be eligible for additional time to regain compliance, or may face delisting.お知らせ • Nov 23Ocean Biomedical Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QOcean Biomedical, Inc. announced that on November 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023. The current notice will have no immediate effect on the listing or trading of Ocean Biomedical’s common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the company’s common stock. On October 16, 2024, Staff notified the Company that since it failed to timely file its Form 10-K for the year ended December 31, 2023, and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024, the Company’s securities were subject to delisting. The Company is now delinquent in the filing its form 10-Q for the period ended September 30, 2024. Accordingly, this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. This is formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in their decision regarding the Company’s continued listing on The Nasdaq Capital Market, which hearing is scheduled for December 16, 2024. The Company intends to file the delinquent Forms 10-Q and 10-K as soon as practicable.New Risk • Nov 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-US$75m). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (€28.0m market cap, or US$30.4m).お知らせ • Oct 23Ocean Biomedical Receives Non-Compliance Letter from NasdaqOcean Biomedical, Inc. announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq Stock Market LLC stating that on April 18, 2024, May 22, 2024, and August 19, 2024, Staff notified the Company that it did not comply with Nasdaq's filing requirements set in Listing Rule 5250(c)(1) (the "Rule") because it had not filed its Form 10-K for the year ended December 31, 2024, and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024 (the "Forms 10-Q"), respectively. Based on its review and the materials submitted on June 17, 2024 and August 27, 2024, Staff granted the Company an exception until October 14, 2024, to regain compliance with the Rule. Upon further review, Staff determined that the Company did not meet the terms of the exception. Specifically, the Company has not filed the either its Form 10-K or Forms 10-Q as required by the Rule. The Company will appeal Staff's determination to a Hearings Panel, pursuant to the procedures set in the Nasdaq Listing Rule 5800 Series.お知らせ • Oct 01Ocean Biomedical, Inc. Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and Its Ability to Inhibit Anti-Tumor and Related Tissue Remodeling ResponsesOcean Biomedical, Inc. announced that Scientific Co-founder Dr. Jack A. Elias, MD, PhD, and colleagues have published new research in the Journal of Immunology that expands understanding of how CHI3L1 inhibits the body's natural immune responses to lung cancers and related diseases such as chronic obstructive pulmonary disease (COPD). This research demonstrates for the first time the complex ways that CHI3L1 inhibits macrophage phagocytosis by stimulating two key phagocytosis checkpoint pathways. The paper notes, " This inhibition of innate immune responses such as phagocytosis provides a mechanistic explanation for the ability of CHI3L1 to stimulate immune checkpoint inhibitors (ICPs) and inhibit essential adaptive immune responses in cancer and COPD. The ability of CHI3L 1 to simultaneously inhibit innate immune responses, stimulate ICPs, inhibit T cell costimulation, and regulate a number of other oncogenic and inflammation pathways suggests that CHI3L1-targeted therapeutics are promising interventions in cancer, COPD, and other disorders." Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. The announced discoveries were based solely on laboratory and animal studies. Ocean Biomedical has not conducted any studies that show similar efficacy or safety in humans. There can be no assurances that this treatment will prove safe or effective in humans, and that any clinical benefits of this treatment is subject to clinical trials and ultimate approval of its use in patients by the FDA. Such approval, if granted, could be years away.お知らせ • Aug 27Ocean Biomedical, Inc. Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention PlatformsOcean Biomedical, Inc. announced that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE, Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of malaria zones, and their control of that mechanism. Their expanded insights have already led to: 1.) a powerful vaccine candidate targeted for long term prevention of malaria infection; 2.) a therapeutic antibody candidate for short term malaria prevention; and 3.) a therapeutic small molecule drug candidate targeted to treat severe malaria, with potential to launch a whole new class of malaria medicines. This patent is adding to Ocean Biomedical's global patent portfolio of over 5 dozen patents for discoveries with potential to impact major unmet medical needs in infectious disease, oncology, and fibrosis, developed through grants totaling over $125 million. Kurtis' novel approach causes parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This patent expands protection for Dr. Kurtis’ novel discoveries at a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs.お知らせ • Aug 25Ocean Biomedical Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QOcean Biomedical, Inc. announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the ‘Form 10-Q’), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the ‘SEC’). Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023. The current notice will have no immediate effect on the listing or trading of Ocean Biomedical’s common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the company’s common stock. Nasdaq indicated that the Company must: (i) no later than September 3, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before October 14, 2024, file the delinquent Form10-Q, along with the delinquent Form 10-Q for the quarter ended March 31, 2024 and the delinquent 10-K for the year ended December 31, 2023. The Company intends to file the delinquent Forms 10-Q and 10-K as soon as practicable.Board Change • Aug 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Founder, Chairman of Scientific Advisory Board & Director Jake Kurtis was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Jul 03Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 3000 IndexOcean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 3000 Indexお知らせ • May 31Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QOcean Biomedical, Inc. announced that on May 22, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC"). As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023. The current notice will have no immediate effect on the listing or trading of Ocean Biomedical's common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the company's common stock. Nasdaq indicated that the Company must: (i) no later than June 14, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before October 14, 2024, file the delinquent Form10-Q. The Company intends to file the delinquent Form 10-Q as soon as practicable.お知らせ • May 16Ocean Biomedical, Inc. announced delayed 10-Q filingOn 05/14/2024, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 25Ocean Biomedical Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KOcean Biomedical, Inc. announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) stating that because the Company has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the ‘Form 10-K’), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the ‘SEC’). As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-K as a result of previously disclosed developments with respect to filing of its amended 10-Qs for the first two quarters of 2023 and filing its 10-Q for the third quarter of 2023. The current notice will have no immediate effect on the listing or trading of Ocean Biomedical’s common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-K will not have an impact on the listing or trading of the company’s common stock. Nasdaq indicated that the Company must: (i) no later than June 14, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before October 14, 2024, file the delinquent Form10-K. The Company intends to file the delinquent Form 10-K as soon as practicable.お知らせ • Apr 02Ocean Biomedical, Inc. announced delayed annual 10-K filingOn 04/01/2024, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 10Ocean Biomedical, Inc. Appoints Amy Griffith as DirectorOcean Biomedical, Inc. announce that on March 4, 2024, Amy Griffith has been appointed as a director. Ms. Griffith currently serves as Head, Government Relations & External Affairs for McCain Foods - North America. She is responsible for the NA Public Affairs strategy and provides strategic leadership and direction on behalf of McCain with policymakers in the United States and Canada. She leads external communications and stakeholder management. Previously, she was the Group Director for the North America Operating unit of the Coca-Cola Company, in this capacity she oversaw public affairs, government relations, sustainability and communications in Canada and the Northeastern United States. Previously, she served as Wells Fargo’s State & Local Government Relations Senior Vice President. She was recruited to Wells Fargo’s Government Relations and Public Policy team in 2019. In this role, Griffith led Wells Fargo’s legislative and political agenda in her region and managed relationships with state and local policymakers and community stakeholders. From 2008-2019, Ms. Griffith led government relations for sixteen states in the Eastern United States for TIAA for over a decade. Prior to that, she worked in the aerospace, high tech, education, private and public sectors, and has managed multiple high-profile political campaigns at the local, state and national level. Griffith serves as an Independent Director for AgriFORCE Growing Systems where she chairs the governance committee. She is a graduate of Gwynedd-Mercy College and holds a Bachelor of Arts in History.New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Negative equity (-US$8.4m). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$63m net loss next year). Market cap is less than US$100m (€55.5m market cap, or US$60.0m).お知らせ • Jan 21Ocean Biomedical Receives Non-Compliance Notice from NasdaqOn January 17, 2024, Ocean Biomedical, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that for the last thirty (30) consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) has been below the minimum requirement of $35 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on the Nasdaq Capital Market under the symbol “OCEA”. Under Nasdaq Listing Rule 5810(c)(3)(C), Company has 180 calendar days, or until July 15, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(2). To regain compliance with Nasdaq Listing Rule 5550(b)(2), the Company’s MVLS must close at $35 million or more for a minimum of ten consecutive business days. If the Company does not regain compliance with Rule 5550(b)(2) by July 15, 2024, the Company will receive written notification from Nasdaq that its securities are subject to delisting. In the event of such a notification, the Company may appeal the delisting determination to a Hearings Panel. The Company intends to monitor its MVLS and consider available options to regain compliance with Nasdaq’s continued listing standards. While the Company is exercising diligent efforts to maintain the listing of the Common Stock on the Nasdaq Capital Market, there can be no assurance that the Company will be successful in maintaining its listing of its common stock on the Nasdaq Capital Market.お知らせ • Jan 18Ocean Biomedical Receives Non-Compliance Notice from NasdaqOn January 11, 2024, Ocean Biomedical, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock between November 28, 2023 and January 10, 2024, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market. The Notification Letter provides that the Company has 180 calendar days, or until July 9, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by July 9, 2024, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.お知らせ • Dec 06Ocean Biomedical Announces Publication of Breast Cancer Research Uncovering New Tumor Suppression Pathway for its Proprietary Anti-Chi3L1 AntibodyOcean Biomedical, Inc. announced that its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple negative breast cancer. The discoveries by a team led by Dr. William Muller at McGill University and in collaboration with Dr. Elias demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from contacting and killing the breast cancer tumor. Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth. This paper deepens the understanding of how CHI3L1 inhibits the body’s natural ability to fight breast cancer tumors. It reveals for the first time another complex pathway by which CHI3L1 inhibits the immune response to cancer, this time by inducing neutrophil recruitment and NETosis, which blocks T cell infiltration. The paper also provides yet another preclinical demonstration of the effectiveness of Ocean’s Anti-CHI3L1 antibody in reducing the tumor growth by targeting CHI3L1 and reversing the T cell blockade. This tumor control pathway, the paper asserts, is likely at work in a range of cancers beyond breast cancer, and “targeting CHI3L1 may promote anti-tumor immunity in various tumor types.” Prior research has established that elevated Chi3L1 levels are associated with many cancers, including glioblastoma, and may be targeted therapeutically. Recent studies from Ocean Biomedical have demonstrated that CHI3L1 is a critical regulator of a number of key cancer-causing pathways, highlighting its ability to inhibit tumor cell death (apoptosis), its inhibition of the expression of the tumor suppressors P53, PTEN, retinoblastoma 1, and Keap1 and its stimulation of the B-RAF protooncogene. Most recently Dr. Elias’s research team has discovered that CHI3L1 is a “master regulator” of ICPI, including key elements of the PD-1 and CTLA4 pathways. In accord with the importance of these pathways, Ocean has also generated antibodies: 1.) a monoclonal antibody against CHI3L1, 2.) bispecific antibodies that simultaneously target CHI3L1 and PD-1, and 3.) a new bispecific antibody that simultaneously targets CHI3L1 and CTLA4.お知らせ • Dec 01Ocean Biomedical Receives a Notice from the Nasdaq Listing Qualifications DepartmentOn November 15, 2023, Ocean Biomedical, Inc. filed a Notification of Late Filing on Form 12b-25 with the Securities Exchange Commission, indicating that the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2023 would be delayed, after determining that it was unable, without unreasonable effort or expense, to file the Form 10-Q by the due date of November 14, 2023. The Company received a notice on November 22, 2023, from the Nasdaq Listing Qualifications Department indicating that the Company remains in non-compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the SEC. The Notice will have no immediate effect on the listing or trading of the Company’s common stock, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the Company’s common stock. Nasdaq indicated that the Company must: (i) no later than January 22, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before May 20, 2024, file the delinquent Form 10-Q. The Company intends to file the delinquent Form 10-Q as soon as practicable.お知らせ • Nov 17Ocean Biomedical, Inc. announced delayed 10-Q filingOn 11/15/2023, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Ocean Biomedical, Inc. Announces Positive Preclinical Oncology Data for Vron 0300, Presented At Sitc 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion TherapeuticsOcean Biomedical, Inc. announced that its joint venture partner, Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, recently presented highly compelling preclinical oncology data. Virion Therapeutics is developing novel immunotherapies that utilize proprietary genetically encoded checkpoint modifiers (CPMs) to enhance and broaden CD8(+) T cells responses. gD BTLA-HVEM Blockade Enhances and Broadens T Cell Activation Preclinical studies using CPMs have shown consistent and extraordinary immune responses and clinical activity in different diseases. In addition to the recently presented oncology data, Virion has recently begun enrolling their Phase 1b clinical trial for persons with chronic hepatitis B virus (HBV): ON-020000 for Chronic Hepatitis B Virus (HBV): VRON-0300 is being developed with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide. It has been designed to help overcome a key cause of chronic HBV, immune exhaustion, by stimulating a patient's own immune response to help control the infection. According to Precedence Research, functional cure for chronic HBV represents an estimated market opportunity of $6.5B+ by 2032. In addition to the recent major clinical and scientific milestones achieved through its Joint Venture partner, Ocean continues to advance immunotherapies for lung, brain, and other cancers by targeting chitinase 3-like-1 expression (CHi3L1) and continues to progress additional development programs in fibrosis and for the treatment, and prevention, ofmalaria.株主還元8AW0DE BiotechsDE 市場7D0%-1.4%-2.6%1Y-98.9%14.7%-0.1%株主還元を見る業界別リターン: 8AW0過去 1 年間で14.7 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 8AW0は、過去 1 年間で-0.1 % のリターンを上げたGerman市場を下回りました。価格変動Is 8AW0's price volatile compared to industry and market?8AW0 volatility8AW0 Average Weekly Movementn/aBiotechs Industry Average Movement8.3%Market Average Movement5.4%10% most volatile stocks in DE Market12.6%10% least volatile stocks in DE Market2.8%安定した株価: 8AW0の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の8AW0のボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20197n/awww.oceanbiomedical.comバイオ医薬品企業であるオーシャン・バイオメディカル社は、米国でがん、線維症、感染症の治療薬の発見と開発に注力している。非小細胞肺がんおよび多形性膠芽腫の治療薬として、Chi3l1を阻害する抗体治療薬候補、Chi3l1＋PD-1＋CTLA-4を阻害する二重特異性抗体候補、特発性肺線維症およびHermansky-Pudlak症候群の治療薬としてChit1を標的とする低分子製品候補を開発している。また、全プロテオーム・ディファレンシャル・スクリーニング・ターゲット・ディスカバリープラットフォームに基づき、マラリア原虫Schizont Egress Antigen-1（PfSEA-1）および／またはマラリア原虫Glutamic Acid Rich Protein（PfGARP）に対するマラリアワクチン候補、PfGARPを標的とするヒト化mAbマラリア治療薬候補、PfGARPを標的とする低分子マラリア治療薬候補など、3つの製品候補を開発している。エルクルト社とは、FRG抗体、二重特異性抗体抗CTLA4、二重特異性（FRG）x抗PD-1（FRGxPD-1）、chit1低分子抗線維化薬、マラリア低分子および抗体に関するライセンス契約を締結している。同社は2019年に設立され、ロードアイランド州プロビデンスを拠点としている。オーシャン・バイオメディカル社はポセイドン・バイオ社の子会社である。もっと見るOcean Biomedical, Inc. 基礎のまとめOcean Biomedical の収益と売上を時価総額と比較するとどうか。8AW0 基礎統計学時価総額€1.26m収益（TTM）-€26.53m売上高(TTM)n/a0.0xP/Sレシオ0.0xPER（株価収益率8AW0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計8AW0 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$30.72m収益-US$30.72m直近の収益報告Mar 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.13グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-16.6%8AW0 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/08/03 05:05終値2025/05/06 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ocean Biomedical, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Michael KingD. Boral Capital LLC.Howard HalpernTaglich Brothers, Inc.
お知らせ • Aug 15Ocean Biomedical, Inc. announced delayed 10-Q filingOn 08/14/2025, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 06Ocean Biomedical Provides Update on the Decision of the Nasdaq Listing and Hearing Review CouncilOn July 31, 2025, Ocean Biomedical, Inc. was notified by Nasdaq that The Nasdaq Stock Market LLC Board of Directors has declined to call for review the May 15, 2025 decision of the Nasdaq Listing and Hearing Review Council in the Company’s appeal proceeding. Accordingly, pursuant to Nasdaq Rule 5820(e)(6), the decision of the Listing Council represents Nasdaq’s final action in this matter. Nasdaq will follow the procedures contained in Nasdaq Rule 5830 and the Securities and Exchange Commission (“SEC”) Rule 12d2-2 to remove the Company’s securities from listing.
お知らせ • Jul 26Ocean Biomedical Receives the Decision of the Nasdaq Listing and Hearing Review CouncilOn July 17, 2025, Ocean Biomedical, Inc. received the decision of the Nasdaq Listing and Hearing Review Council pursuant to an appeal by the Company. On April 22, 2025, the Nasdaq Hearings Panel (the “Panel”) issued a decision to delist the Company’s securities from The Nasdaq Stock Market, LLC (the “Exchange” or “Nasdaq”) and suspend trading of the Company’s shares, effective at the opening of business on April 24, 2025. The Company appealed the Panel’s decision to the Listing Council. After considering the written record in this matter, the Listing Council affirms the Panel’s decision to delist the Company from the Nasdaq affirming Nasdaq’s delist decision letter dated April 22, 2025.
お知らせ • Apr 24+ 1 more updateOcean Biomedical, Inc.(OTCPK:OCEA) dropped from NASDAQ Composite IndexOcean Biomedical, Inc. has been dropped from the NASDAQ Composite Index (^COMP).
お知らせ • Apr 02Ocean Biomedical, Inc. announced delayed annual 10-K filingOn 04/01/2025, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 29Ocean Biomedical, Inc. Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in ChinaOcean Biomedical, Inc. announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells. This newly issued patent will strengthen Ocean Biomedical's intellectual property portfolio and provides protection in one of the world's largest pharmaceutical markets. The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 andPD1, key targets implicated in immune evasion by tumor cells. Ocean Biomedical's bispecific antibody technology represents a potential paradigm shift in cancer immunotherapy. By simultaneously targeting CHI3L1--a key regulator of immune suppression--and PD1, a well-established immune checkpoint, this novel approach has the potential to reinvigorate the immune system's ability to combat tumors more effectively than existing treatments alone. By blocking both pathways, these antibodies could enhance immune-mediated tumor cell destruction, leading to more durable responses and better outcomes for patients. Current immunotherapies are often limited by tumor resistance and immune evasion mechanisms. Ocean Biomedical's technology seeks to address these limitations by taking a multi-pronged approach, blocking two key pathways that tumors use to suppress the immune response. This could result in more robust and sustained tumor control, significantly improving survival rates for patients who currently have limited treatment options. The grant of this patent follows Ocean Biomedical's continued success in securing intellectual property protection across key markets, including the United States and Europe. The company remains committed to leveraging its robust patent estate to drive the development and commercialization of novel immunotherapies. Ocean Biomedical plans to continue collaborating with leading researchers, biopharma partners, and regulatory agencies to strive to accelerate the translation of its discoveries into transformative therapies.
お知らせ • Aug 15Ocean Biomedical, Inc. announced delayed 10-Q filingOn 08/14/2025, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 06Ocean Biomedical Provides Update on the Decision of the Nasdaq Listing and Hearing Review CouncilOn July 31, 2025, Ocean Biomedical, Inc. was notified by Nasdaq that The Nasdaq Stock Market LLC Board of Directors has declined to call for review the May 15, 2025 decision of the Nasdaq Listing and Hearing Review Council in the Company’s appeal proceeding. Accordingly, pursuant to Nasdaq Rule 5820(e)(6), the decision of the Listing Council represents Nasdaq’s final action in this matter. Nasdaq will follow the procedures contained in Nasdaq Rule 5830 and the Securities and Exchange Commission (“SEC”) Rule 12d2-2 to remove the Company’s securities from listing.
お知らせ • Jul 26Ocean Biomedical Receives the Decision of the Nasdaq Listing and Hearing Review CouncilOn July 17, 2025, Ocean Biomedical, Inc. received the decision of the Nasdaq Listing and Hearing Review Council pursuant to an appeal by the Company. On April 22, 2025, the Nasdaq Hearings Panel (the “Panel”) issued a decision to delist the Company’s securities from The Nasdaq Stock Market, LLC (the “Exchange” or “Nasdaq”) and suspend trading of the Company’s shares, effective at the opening of business on April 24, 2025. The Company appealed the Panel’s decision to the Listing Council. After considering the written record in this matter, the Listing Council affirms the Panel’s decision to delist the Company from the Nasdaq affirming Nasdaq’s delist decision letter dated April 22, 2025.
お知らせ • Apr 24+ 1 more updateOcean Biomedical, Inc.(OTCPK:OCEA) dropped from NASDAQ Composite IndexOcean Biomedical, Inc. has been dropped from the NASDAQ Composite Index (^COMP).
お知らせ • Apr 02Ocean Biomedical, Inc. announced delayed annual 10-K filingOn 04/01/2025, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 29Ocean Biomedical, Inc. Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in ChinaOcean Biomedical, Inc. announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells. This newly issued patent will strengthen Ocean Biomedical's intellectual property portfolio and provides protection in one of the world's largest pharmaceutical markets. The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 andPD1, key targets implicated in immune evasion by tumor cells. Ocean Biomedical's bispecific antibody technology represents a potential paradigm shift in cancer immunotherapy. By simultaneously targeting CHI3L1--a key regulator of immune suppression--and PD1, a well-established immune checkpoint, this novel approach has the potential to reinvigorate the immune system's ability to combat tumors more effectively than existing treatments alone. By blocking both pathways, these antibodies could enhance immune-mediated tumor cell destruction, leading to more durable responses and better outcomes for patients. Current immunotherapies are often limited by tumor resistance and immune evasion mechanisms. Ocean Biomedical's technology seeks to address these limitations by taking a multi-pronged approach, blocking two key pathways that tumors use to suppress the immune response. This could result in more robust and sustained tumor control, significantly improving survival rates for patients who currently have limited treatment options. The grant of this patent follows Ocean Biomedical's continued success in securing intellectual property protection across key markets, including the United States and Europe. The company remains committed to leveraging its robust patent estate to drive the development and commercialization of novel immunotherapies. Ocean Biomedical plans to continue collaborating with leading researchers, biopharma partners, and regulatory agencies to strive to accelerate the translation of its discoveries into transformative therapies.
お知らせ • Feb 17Ocean Biomedical, Inc., Annual General Meeting, Mar 28, 2025Ocean Biomedical, Inc., Annual General Meeting, Mar 28, 2025. Location: 2511 redwood road, suite 16, utah 84087., woods cross, United States
お知らせ • Feb 11Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage DevelopmentOcean Biomedical announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI), such as osimertinib that are used to treat non-small cell lung cancer (NSCLC). Specifically, they demonstrate that Ocean’s immunotherapy candidates provide synergy with the TKI therapies (gefitinib and osimertinib) to suppress tumor growth and progression. In addition, the paper’s findings demonstrate that its proprietary cancer immunotherapy candidates have a remarkable ability to restore treatment sensitivity following development of osimertinib resistance. This breakthrough offers a potential paradigm shift in the treatment of Epidermal Growth Factor Receptor (EGFR)-mutant NSCLC and could expand treatment options for patients whose tumors are no longer responding to tyrosine kinase inhibitors. These findings, led by Ocean Biomedical’s Scientific Co-founder Dr. Jack A. Elias in collaboration with researchers at Yale University and Brown University, were published in Translational Oncology and mark the first description of the role of chitinase 3-like-1 (CHi3L1) in EGFR-mutant cancers. The research underscores the ability of Ocean Biomedical’s novel antibody to suppress CHi3L1 activity, leading to significant tumor reduction and, crucially, the reversal of drug resistance in preclinical models. As part of its continued commitment to developing next-generation cancer therapeutics, Ocean Biomedical is initiating preclinical studies to advance its immunotherapy program and will engage with the FDA this year to align on a regulatory pathway for first-in-human trials. Ocean Biomedical’s advancements come at a time when the oncology field is shifting its focus towards bispecific antibodies, an innovative therapeutic class designed to target multiple cancer mechanisms simultaneously. Bispecific antibodies that target PD-1/PD-L1 and VEGF have shown remarkable efficacy in recent clinical studies, with leading biotech and pharmaceutical companies rapidly investing in this space. Merck’s recent $588 million acquisition of LaNova’s LM-299, a PD-1/VEGF bispecific antibody currently in early-stage clinical trials, underscores the high-value potential of this technology. Industry experts suggest that this wave of investments mirrors the early days of checkpoint inhibitors, highlighting the significant opportunity for Ocean Biomedical to position itself at the forefront of the next major oncology breakthrough. Ocean has also developed bispecific antibodies that combine its anti-CHI3L1 antibody and anti-PD-1 or anti-CTLA4. Studies with these bispecific antibodies have highlighted their impressive efficacy in suppressing tumor growth and progression in preclinical models of NSCLC, malignant melanoma and glioblastoma. The company’s lead oncology program is poised for multiple therapeutic applications: As a standalone therapy for EGFR-mutant NSCLC, In combination with existing TKIs to extend therapeutic response duration, As a salvage therapy to restore treatment efficacy in resistant tumors. With plans to initiate preclinical studies this year, Ocean Biomedical is actively preparing for discussions with the FDA to determine the regulatory pathway for clinical development. This milestone marks a significant step toward bringing its innovative cancer therapy to patients in need.
お知らせ • Jan 30Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development PathwayOcean Biomedical announced that its Scientific Co-founder, Dr. Jonathan Kurtis, MD, PhD, and his research team have received additional significant funding from the National Institutes of Health (NIH) to advance their malaria vaccine research. In parallel, recent U.S. Food and Drug Administration (FDA) Guidance on lipid-encapsulated vaccines may offer an expedited development pathway for their innovative approach. Malaria remains a devastating global health challenge, claiming the lives of over 500,000 children annually in sub-Saharan Africa. Despite hundreds of vaccine development efforts, few have succeeded, largely due to ineffective target selection strategies. Through longitudinal studies of children frequently exposed to infected mosquitoes, the researchers identified a unique protein--glutamic acid-rich protein (GARP)--on the surface of malaria-infected red blood cells. Notably, children who naturally resist severe malaria were found to have developed antibodies against GARP. This discovery, supported by multiple NIH and non-governmental grants, has paved the way for vaccine development. With the support of a $4.6 million non-governmental Foundation grant, Dr. Kurtis' team is now testing three vaccine candidates in non-human primates. The research also explores the feasibility of using lipid-encapsulated messenger ronucleic acid (mRNA) technology as a delivery mechanism. Building on clinical data from millions of individuals who received lipid-encapsulated mRNA vaccines, the FDA has issued new guidance that could facilitate a faster transition to first-in-human trials. Ocean Biomedical intends to leverage this opportunity, with a potential to initiate human trials as early as fourth quarter 2025.
お知らせ • Jan 15Ocean Biomedical, Inc. Receives Non-Compliance Notice from Nasdaq Regarding Listing Rules 5620(a) and 5810(c)(2)(G)On January 7, 2025, Ocean Biomedical, Inc. received a notice from Nasdaq that since the Company had not yet held an annual meeting of shareholders within twelve months of the Company's fiscal year ended December 31, 2023, it no longer complies with the Listing Rules (the Rules") for continued listing.(Listing Rules 5620(a) and 5810(c)(2)(G)). Accordingly, this matter serves as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. This is formal notification that the Nasdaq Hearings Panel (the Panel") will consider this matter in their decision regarding the Company's continued listing on The Nasdaq Capital Market. In that regard, the Company should present its views with respect to this additional deficiency to the Panel in writing no later than January 14, 2025. The Company plans on holding its annual meeting no later than March 31, 2025.
お知らせ • Dec 12Ocean Biomedical Receives Non-Compliance Letter Regarding Nasdaq MVLSOn December 5, 2024, Nasdaq sent a letter to Ocean Biomedical, Inc. notifying it that based upon the Company's MVLS for the last 30 consecutive business days, the Company no longer meets this requirement. Consequently, a deficiency exists with regard to the Rule. However, the Rules also provide the Company a compliance period of 180 calendar days in which to regain compliance. If at anytime during this compliance period the Company's MVLS closes at $35 million or more for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the Rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting and it may be eligible for additional time to regain compliance, or may face delisting.
お知らせ • Dec 10Ocean Biomedical Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid PriceOn December 3, 2024, Ocean Biomedical, Inc. (the Company") received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq's Listing Rules (the Rules") which require listed securities to maintain a minimum bid price of $1 per share. Based upon the closing bid price for the last 30 consecutive business days (October 21, 2024 to December 2, 2024), the Company no longer meets this requirement. However, the Rules also provide the Company a compliance period of 180 calendar days (until June 2, 2025) in which to regain compliance. Pursuant to Rule 5810(c)(3)(C) if at any time during this 180 day period the closing bid price of the Company's security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by June 2, 2025, the Company may be eligible for additional time to regain compliance, or may face delisting.
お知らせ • Nov 23Ocean Biomedical Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QOcean Biomedical, Inc. announced that on November 18, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission. Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023. The current notice will have no immediate effect on the listing or trading of Ocean Biomedical’s common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the company’s common stock. On October 16, 2024, Staff notified the Company that since it failed to timely file its Form 10-K for the year ended December 31, 2023, and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024, the Company’s securities were subject to delisting. The Company is now delinquent in the filing its form 10-Q for the period ended September 30, 2024. Accordingly, this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. This is formal notification that the Nasdaq Hearings Panel (the “Panel”) will consider this matter in their decision regarding the Company’s continued listing on The Nasdaq Capital Market, which hearing is scheduled for December 16, 2024. The Company intends to file the delinquent Forms 10-Q and 10-K as soon as practicable.
New Risk • Nov 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-US$75m). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (€28.0m market cap, or US$30.4m).
お知らせ • Oct 23Ocean Biomedical Receives Non-Compliance Letter from NasdaqOcean Biomedical, Inc. announced that on October 16, 2024, it received a Staff Determination Letter from The Nasdaq Stock Market LLC stating that on April 18, 2024, May 22, 2024, and August 19, 2024, Staff notified the Company that it did not comply with Nasdaq's filing requirements set in Listing Rule 5250(c)(1) (the "Rule") because it had not filed its Form 10-K for the year ended December 31, 2024, and its Forms 10-Q for the periods ended March 31, 2024 and June 30, 2024 (the "Forms 10-Q"), respectively. Based on its review and the materials submitted on June 17, 2024 and August 27, 2024, Staff granted the Company an exception until October 14, 2024, to regain compliance with the Rule. Upon further review, Staff determined that the Company did not meet the terms of the exception. Specifically, the Company has not filed the either its Form 10-K or Forms 10-Q as required by the Rule. The Company will appeal Staff's determination to a Hearings Panel, pursuant to the procedures set in the Nasdaq Listing Rule 5800 Series.
お知らせ • Oct 01Ocean Biomedical, Inc. Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and Its Ability to Inhibit Anti-Tumor and Related Tissue Remodeling ResponsesOcean Biomedical, Inc. announced that Scientific Co-founder Dr. Jack A. Elias, MD, PhD, and colleagues have published new research in the Journal of Immunology that expands understanding of how CHI3L1 inhibits the body's natural immune responses to lung cancers and related diseases such as chronic obstructive pulmonary disease (COPD). This research demonstrates for the first time the complex ways that CHI3L1 inhibits macrophage phagocytosis by stimulating two key phagocytosis checkpoint pathways. The paper notes, " This inhibition of innate immune responses such as phagocytosis provides a mechanistic explanation for the ability of CHI3L1 to stimulate immune checkpoint inhibitors (ICPs) and inhibit essential adaptive immune responses in cancer and COPD. The ability of CHI3L 1 to simultaneously inhibit innate immune responses, stimulate ICPs, inhibit T cell costimulation, and regulate a number of other oncogenic and inflammation pathways suggests that CHI3L1-targeted therapeutics are promising interventions in cancer, COPD, and other disorders." Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. The announced discoveries were based solely on laboratory and animal studies. Ocean Biomedical has not conducted any studies that show similar efficacy or safety in humans. There can be no assurances that this treatment will prove safe or effective in humans, and that any clinical benefits of this treatment is subject to clinical trials and ultimate approval of its use in patients by the FDA. Such approval, if granted, could be years away.
お知らせ • Aug 27Ocean Biomedical, Inc. Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention PlatformsOcean Biomedical, Inc. announced that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE, Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of malaria zones, and their control of that mechanism. Their expanded insights have already led to: 1.) a powerful vaccine candidate targeted for long term prevention of malaria infection; 2.) a therapeutic antibody candidate for short term malaria prevention; and 3.) a therapeutic small molecule drug candidate targeted to treat severe malaria, with potential to launch a whole new class of malaria medicines. This patent is adding to Ocean Biomedical's global patent portfolio of over 5 dozen patents for discoveries with potential to impact major unmet medical needs in infectious disease, oncology, and fibrosis, developed through grants totaling over $125 million. Kurtis' novel approach causes parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This patent expands protection for Dr. Kurtis’ novel discoveries at a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs.
お知らせ • Aug 25Ocean Biomedical Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QOcean Biomedical, Inc. announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the ‘Form 10-Q’), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the ‘SEC’). Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023. The current notice will have no immediate effect on the listing or trading of Ocean Biomedical’s common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the company’s common stock. Nasdaq indicated that the Company must: (i) no later than September 3, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before October 14, 2024, file the delinquent Form10-Q, along with the delinquent Form 10-Q for the quarter ended March 31, 2024 and the delinquent 10-K for the year ended December 31, 2023. The Company intends to file the delinquent Forms 10-Q and 10-K as soon as practicable.
Board Change • Aug 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Founder, Chairman of Scientific Advisory Board & Director Jake Kurtis was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Jul 03Ocean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 3000 IndexOcean Biomedical, Inc.(NasdaqCM:OCEA) dropped from Russell 3000 Index
お知らせ • May 31Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QOcean Biomedical, Inc. announced that on May 22, 2024, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the "SEC"). As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-Q as a result of previously disclosed developments with respect to filing of its 10-K for the year ended December 31, 2023. The current notice will have no immediate effect on the listing or trading of Ocean Biomedical's common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the company's common stock. Nasdaq indicated that the Company must: (i) no later than June 14, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before October 14, 2024, file the delinquent Form10-Q. The Company intends to file the delinquent Form 10-Q as soon as practicable.
お知らせ • May 16Ocean Biomedical, Inc. announced delayed 10-Q filingOn 05/14/2024, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 25Ocean Biomedical Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KOcean Biomedical, Inc. announced that on April 18, 2024, it received a notice from The Nasdaq Stock Market LLC (‘Nasdaq’) stating that because the Company has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the ‘Form 10-K’), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the ‘SEC’). As previously reported in its SEC filings, Ocean Biomedical is delayed in filing the Form 10-K as a result of previously disclosed developments with respect to filing of its amended 10-Qs for the first two quarters of 2023 and filing its 10-Q for the third quarter of 2023. The current notice will have no immediate effect on the listing or trading of Ocean Biomedical’s common stock on Nasdaq, although there can be no assurances that further delays in the filing of the Form 10-K will not have an impact on the listing or trading of the company’s common stock. Nasdaq indicated that the Company must: (i) no later than June 14, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before October 14, 2024, file the delinquent Form10-K. The Company intends to file the delinquent Form 10-K as soon as practicable.
お知らせ • Apr 02Ocean Biomedical, Inc. announced delayed annual 10-K filingOn 04/01/2024, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 10Ocean Biomedical, Inc. Appoints Amy Griffith as DirectorOcean Biomedical, Inc. announce that on March 4, 2024, Amy Griffith has been appointed as a director. Ms. Griffith currently serves as Head, Government Relations & External Affairs for McCain Foods - North America. She is responsible for the NA Public Affairs strategy and provides strategic leadership and direction on behalf of McCain with policymakers in the United States and Canada. She leads external communications and stakeholder management. Previously, she was the Group Director for the North America Operating unit of the Coca-Cola Company, in this capacity she oversaw public affairs, government relations, sustainability and communications in Canada and the Northeastern United States. Previously, she served as Wells Fargo’s State & Local Government Relations Senior Vice President. She was recruited to Wells Fargo’s Government Relations and Public Policy team in 2019. In this role, Griffith led Wells Fargo’s legislative and political agenda in her region and managed relationships with state and local policymakers and community stakeholders. From 2008-2019, Ms. Griffith led government relations for sixteen states in the Eastern United States for TIAA for over a decade. Prior to that, she worked in the aerospace, high tech, education, private and public sectors, and has managed multiple high-profile political campaigns at the local, state and national level. Griffith serves as an Independent Director for AgriFORCE Growing Systems where she chairs the governance committee. She is a graduate of Gwynedd-Mercy College and holds a Bachelor of Arts in History.
New Risk • Mar 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.9m free cash flow). Share price has been highly volatile over the past 3 months (43% average weekly change). Negative equity (-US$8.4m). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (US$63m net loss next year). Market cap is less than US$100m (€55.5m market cap, or US$60.0m).
お知らせ • Jan 21Ocean Biomedical Receives Non-Compliance Notice from NasdaqOn January 17, 2024, Ocean Biomedical, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that for the last thirty (30) consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) has been below the minimum requirement of $35 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade on the Nasdaq Capital Market under the symbol “OCEA”. Under Nasdaq Listing Rule 5810(c)(3)(C), Company has 180 calendar days, or until July 15, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(2). To regain compliance with Nasdaq Listing Rule 5550(b)(2), the Company’s MVLS must close at $35 million or more for a minimum of ten consecutive business days. If the Company does not regain compliance with Rule 5550(b)(2) by July 15, 2024, the Company will receive written notification from Nasdaq that its securities are subject to delisting. In the event of such a notification, the Company may appeal the delisting determination to a Hearings Panel. The Company intends to monitor its MVLS and consider available options to regain compliance with Nasdaq’s continued listing standards. While the Company is exercising diligent efforts to maintain the listing of the Common Stock on the Nasdaq Capital Market, there can be no assurance that the Company will be successful in maintaining its listing of its common stock on the Nasdaq Capital Market.
お知らせ • Jan 18Ocean Biomedical Receives Non-Compliance Notice from NasdaqOn January 11, 2024, Ocean Biomedical, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock between November 28, 2023 and January 10, 2024, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the common stock will continue to trade on The Nasdaq Capital Market. The Notification Letter provides that the Company has 180 calendar days, or until July 9, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by July 9, 2024, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market, other than the minimum closing bid price requirement and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the delisting determination to a Hearings Panel. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
お知らせ • Dec 06Ocean Biomedical Announces Publication of Breast Cancer Research Uncovering New Tumor Suppression Pathway for its Proprietary Anti-Chi3L1 AntibodyOcean Biomedical, Inc. announced that its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple negative breast cancer. The discoveries by a team led by Dr. William Muller at McGill University and in collaboration with Dr. Elias demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from contacting and killing the breast cancer tumor. Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth. This paper deepens the understanding of how CHI3L1 inhibits the body’s natural ability to fight breast cancer tumors. It reveals for the first time another complex pathway by which CHI3L1 inhibits the immune response to cancer, this time by inducing neutrophil recruitment and NETosis, which blocks T cell infiltration. The paper also provides yet another preclinical demonstration of the effectiveness of Ocean’s Anti-CHI3L1 antibody in reducing the tumor growth by targeting CHI3L1 and reversing the T cell blockade. This tumor control pathway, the paper asserts, is likely at work in a range of cancers beyond breast cancer, and “targeting CHI3L1 may promote anti-tumor immunity in various tumor types.” Prior research has established that elevated Chi3L1 levels are associated with many cancers, including glioblastoma, and may be targeted therapeutically. Recent studies from Ocean Biomedical have demonstrated that CHI3L1 is a critical regulator of a number of key cancer-causing pathways, highlighting its ability to inhibit tumor cell death (apoptosis), its inhibition of the expression of the tumor suppressors P53, PTEN, retinoblastoma 1, and Keap1 and its stimulation of the B-RAF protooncogene. Most recently Dr. Elias’s research team has discovered that CHI3L1 is a “master regulator” of ICPI, including key elements of the PD-1 and CTLA4 pathways. In accord with the importance of these pathways, Ocean has also generated antibodies: 1.) a monoclonal antibody against CHI3L1, 2.) bispecific antibodies that simultaneously target CHI3L1 and PD-1, and 3.) a new bispecific antibody that simultaneously targets CHI3L1 and CTLA4.
お知らせ • Dec 01Ocean Biomedical Receives a Notice from the Nasdaq Listing Qualifications DepartmentOn November 15, 2023, Ocean Biomedical, Inc. filed a Notification of Late Filing on Form 12b-25 with the Securities Exchange Commission, indicating that the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2023 would be delayed, after determining that it was unable, without unreasonable effort or expense, to file the Form 10-Q by the due date of November 14, 2023. The Company received a notice on November 22, 2023, from the Nasdaq Listing Qualifications Department indicating that the Company remains in non-compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the SEC. The Notice will have no immediate effect on the listing or trading of the Company’s common stock, although there can be no assurances that further delays in the filing of the Form 10-Q will not have an impact on the listing or trading of the Company’s common stock. Nasdaq indicated that the Company must: (i) no later than January 22, 2024, submit a plan to regain compliance with respect to the filing requirement; and (ii) on or before May 20, 2024, file the delinquent Form 10-Q. The Company intends to file the delinquent Form 10-Q as soon as practicable.
お知らせ • Nov 17Ocean Biomedical, Inc. announced delayed 10-Q filingOn 11/15/2023, Ocean Biomedical, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Ocean Biomedical, Inc. Announces Positive Preclinical Oncology Data for Vron 0300, Presented At Sitc 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion TherapeuticsOcean Biomedical, Inc. announced that its joint venture partner, Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, recently presented highly compelling preclinical oncology data. Virion Therapeutics is developing novel immunotherapies that utilize proprietary genetically encoded checkpoint modifiers (CPMs) to enhance and broaden CD8(+) T cells responses. gD BTLA-HVEM Blockade Enhances and Broadens T Cell Activation Preclinical studies using CPMs have shown consistent and extraordinary immune responses and clinical activity in different diseases. In addition to the recently presented oncology data, Virion has recently begun enrolling their Phase 1b clinical trial for persons with chronic hepatitis B virus (HBV): ON-020000 for Chronic Hepatitis B Virus (HBV): VRON-0300 is being developed with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide. It has been designed to help overcome a key cause of chronic HBV, immune exhaustion, by stimulating a patient's own immune response to help control the infection. According to Precedence Research, functional cure for chronic HBV represents an estimated market opportunity of $6.5B+ by 2032. In addition to the recent major clinical and scientific milestones achieved through its Joint Venture partner, Ocean continues to advance immunotherapies for lung, brain, and other cancers by targeting chitinase 3-like-1 expression (CHi3L1) and continues to progress additional development programs in fibrosis and for the treatment, and prevention, ofmalaria.
